Key result
Extended low-dose apixaban investigated for symptomatic superficial vein thrombosis in provoked VTE with enduring risk factors.
Why the study?
The impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors had not been established.
Does extended low-dose apixaban reduce symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors?
Does extended low-dose apixaban reduce symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors?
This post hoc analysis investigates whether extended low-dose apixaban impacts symptomatic superficial vein thrombosis events in patients with provoked VTE.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“Patients with acute VTE with transient provoking factors, such as surgery, trauma or immobility, typically receive short-term anticoagulation. However, the risk of VTE recurrence may remain high in certain patients with enduring risk factors, including those with obesity, chronic lung disease or autoimmune disorders. In such patients, the optimal duration of anticoagulation is uncertain. We designed the HI-PRO trial to assess the efficacy and safety of extended-duration apixaban 2.5 mg twice daily, compared with placebo, for the prevention of recurrence in patients with provoked VTE and at least one enduring risk factor.”
“Low-intensity apixaban for 12 months effectively reduced symptomatic VTE recurrence with a low risk of major bleeding in patients with provoked VTE and enduring risk factors. Additional research is needed to identify which subgroups benefit most from extended anticoagulation.”
May warrant extended low-dose apixaban in provoked VTE with enduring risks; extends evidence to superficial vein thrombosis but remains hypothesis-generating.
This post hoc analysis of the Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism ( HI-PRO) randomized clinical trial investigates the impact of extended low-dose apixaban on symptomatic superficial vein thrombosis events in patients with provoked venous thromboembolism and enduring risk factors.
Rashedi et al. (2026) studied this question. Extended low-dose apixaban was investigated for its impact on symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism and enduring risk factors.
Synapse has enriched 10 related papers. Consider them for comparative context: